Harvard Bioscience reported earnings of -$ 0.06 per HBIO share on Nov 10, 2026, falling short of analysts' expectations by
| Report Date | Nov 10, 2026 |
|---|---|
| Forecasted EPS | -$ 0.33 |
| Earnings Per Share (Surprise) | -$ 0.06 (+$ 0.27) |
| Last Year's EPS | -$ 0.28 |
| EPS YoY Change |
Out of the last 100 earnings reporting periods, Harvard Bioscience beat analysts’ expectations 45 times and fell short of expectations 20 time(s). Harvard Bioscience reported earnings per share of -$ 0.06 in the last report surpassing an estimated EPS of -$ 0.33 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.33 | -$ 0.06 | -$ 0.28 | |
| Aug 11, 2026 | -$ 0.21 | -$ 0.14 | -$ 0.10 | |
| May 12, 2026 | -$ 0.62 | -$ 0.33 | -$ 0.10 | |
| Mar 12, 2026 | $ 0.04 | -$ 0.64 | $ 0.60 | |
| Nov 6, 2025 | $ 0.05 | -$ 0.28 | -$ 0.20 | |
| Aug 11, 2025 | -$ 0.25 | -$ 0.10 | -$ 0.67 | |
| May 12, 2025 | -$ 0.20 | -$ 0.10 | $ 0.20 | |
| Mar 12, 2025 | $ 0.07 | $ 0.60 | $ 0.04 | |
| Nov 7, 2024 | $ 0.15 | -$ 0.20 | $ 0.01 | |
| Aug 8, 2024 | $ 0.05 | -$ 0.67 | $ 0.04 | |
| May 7, 2024 | $ 0.20 | $ 0.20 | $ 0.06 | |
| Mar 7, 2024 | $ 0.05 | $ 0.04 | $ 0.04 | |
| Nov 7, 2023 | $ 0.04 | $ 0.01 | -$ 0.01 | |
| Aug 8, 2023 | $ 0.06 | $ 0.04 | $ 0.50 | |
| Apr 25, 2023 | $ 0.05 | $ 0.06 | $ 0.04 | |
| Mar 9, 2023 | $ 0.03 | $ 0.04 | $ 0.20 | |
| Nov 8, 2022 | $ 0.06667 | -$ 0.01 | $ 0.60 | |
| Aug 3, 2022 | $ 0.30 | $ 0.50 | $ 0.60 | |
| May 4, 2022 | $ 0.50 | $ 0.04 | $ 0.50 | |
| Mar 8, 2022 | $ 0.90 | $ 0.20 | $ 0.80 |
Harvard Bioscience’s stock was trading at $ 9.09 on Nov 9, 2026 a day before the last earnings report was released.Following the release of the earnings report, HBIO’s price increased to $ 9.68 on Nov 11, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 10, 2026 | -$ 0.06 | $ 9.09 | $ 9.68 | |
| Aug 11, 2026 | -$ 0.14 | $ 6.39 | $ 6.17 | |
| May 12, 2026 | -$ 0.33 | $ 6.84 | $ 5.57 | |
| Mar 12, 2026 | -$ 0.64 | $ 5.07 | $ 4.73 | |
| Nov 6, 2025 | -$ 0.28 | $ 5.89 | $ 5.43 | |
| Aug 11, 2025 | -$ 0.10 | $ 5.28 | $ 4.83 | |
| May 12, 2025 | -$ 0.10 | $ 3.15 | $ 3.71 | |
| Mar 12, 2025 | $ 0.60 | $ 7.62 | $ 6.40 | |
| Nov 7, 2024 | -$ 0.20 | $ 28.20 | $ 25.70 | |
| Aug 8, 2024 | -$ 0.67 | $ 27.90 | $ 29.10 | |
| May 7, 2024 | $ 0.20 | $ 39.20 | $ 36.80 | |
| Mar 7, 2024 | $ 0.04 | $ 41.10 | $ 44.20 | |
| Nov 7, 2023 | $ 0.01 | $ 43.00 | $ 41.90 | |
| Aug 8, 2023 | $ 0.04 | $ 45.20 | $ 43.50 | |
| Apr 25, 2023 | $ 0.06 | $ 49.00 | $ 55.90 | |
| Mar 9, 2023 | $ 0.04 | $ 24.80 | $ 26.70 | |
| Nov 8, 2022 | -$ 0.01 | $ 25.10 | $ 21.90 | |
| Aug 3, 2022 | $ 0.50 | $ 37.20 | $ 36.00 | |
| May 4, 2022 | $ 0.04 | $ 56.50 | $ 41.20 | |
| Mar 8, 2022 | $ 0.20 | $ 54.00 | $ 62.50 |
Harvard Bioscience released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Harvard Bioscience beat analysts’ expectations during the last earnings period by
